List of Xtampza Er drug patents

Xtampza Er is owned by Collegium Pharm Inc.

Xtampza Er contains Oxycodone.

Xtampza Er has a total of 19 drug patents out of which 0 drug patents have expired.

Xtampza Er was authorised for market use on 26 April, 2016.

Xtampza Er is available in capsule, extended release;oral dosage forms.

Xtampza Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The generics of Xtampza Er are possible to be released after 02 September, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248195 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(5 months from now)

US8840928 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Jul, 2023

(5 months from now)

US10525052 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jul, 2023

(5 months from now)

US9044398 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Jul, 2023

(5 months from now)

US9592200 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(5 months from now)

US9763883 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jul, 2023

(5 months from now)

US10525053 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Jul, 2023

(5 months from now)

US8557291 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opioids and other drugs
Mar, 2025

(2 years from now)

US8449909 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(2 years from now)

US7399488 COLLEGIUM PHARM INC Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Mar, 2025

(2 years from now)

US7771707 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Mar, 2025

(2 years from now)

US8758813 COLLEGIUM PHARM INC Abuse-deterrent drug formulations
Jun, 2025

(2 years from now)

US9682075 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Dec, 2030

(7 years from now)

US10668060 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Dec, 2030

(7 years from now)

US10004729 COLLEGIUM PHARM INC Tamper-resistant pharmaceutical compositions of opioids and other drugs
Dec, 2030

(7 years from now)

US10188644 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(13 years from now)

US9968598 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(13 years from now)

US10646485 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(13 years from now)

US9737530 COLLEGIUM PHARM INC Process of making stable abuse-deterrent oral formulations
Sep, 2036

(13 years from now)

Drugs and Companies using OXYCODONE ingredient

Market Authorisation Date: 26 April, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of XTAMPZA ER before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in